Lupin has incorporated wholly-owned subsidiary namely ‘Lupinlife Consumer Healthcare’. The company has received certificate of incorporation from Ministry of Corporate Affairs on March 18, 2025.
Earlier, the company had received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Amifampridine Tablets, 10 mg.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
